MARÍA CRISTINA
CHURRUCA GALAZ
Hospital Universitario de Donostia
San Sebastián, EspañaPublications in collaboration with researchers from Hospital Universitario de Donostia (9)
2024
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 184, pp. 168-177
-
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
2023
-
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 30, pp. 4768-4778
-
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4068-4075
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
-
Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after
Quality of Life Research, Vol. 32, Núm. 4, pp. 989-1003
2022
2021
-
Factors that Influence Treatment Delay for Patients with Breast Cancer
Annals of Surgical Oncology, Vol. 28, Núm. 7, pp. 3714-3721